Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
European Organisation for Research and Treatment of Cancer - EORTC
Objective 1: To identify germline allelic DNA variation associated with somatic EGFR mutation in NSCLC, Objective 2: Correlation between germline allelic variants and survival in EGFR somatic mutant NSCLC.
Objective 3: Study germline allelic DNA variation associated with never /ex light smoking NSCLC.
Objective 4: Catalogue distribution of somatic EGFR mutant genotypes in 1,000 EGFR mutant NSCLC cases and describe their relationship to clinical outcome.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically diagnosed NSCLC, all histologies are acceptable.
Patients can be included in the study with any disease stage and at any time during the disease course.
Any type (surgery, RadioTherapy, chemotherapy, targeted agents) of previous treatment and any line of treatment are eligible.
Age ≥18 years.
Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient before registration in the trial.
Before patient registration, written informed consent must be given according to ICH/GCP (International Conference on Harmonisation/Good Clinical Practice), and national/local regulations.